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Objectives. To characterize tumour baseline blood flow (BF) in two lung cancer subtypes, adenocarcinoma (AC) and squamous
cell carcinoma (SCC), also investigating those “borderline” cases whose perfusion value is closer to the group mean of the other
histotype. Materials and Methods. 26 patients (age range 36-81 years) with primary Non-Small Cell Lung Cancer (NSCLC),
subdivided into 19 AC and 7 SCC, were enrolled in this study and underwent a CT perfusion, at diagnosis. BF values were computed
according to the maximum-slope method and unreliable values (e.g., arising from artefacts or vessels) were automatically removed.
The one-tail Welch’s t-test (𝑝-value < 0.05) was employed for statistical assessment. Results. At diagnosis, mean BF values (in
[mL/min/100g]) of AC group [(83.5 ± 29.4)] are significantly greater than those of SCC subtype [(57.0 ± 27.2)] (𝑝-value = 0.02).
However, two central SCCs undergoing artefacts from vena cava and pulmonary artery have an artificially increased mean BF.
Conclusions. The different hemodynamic behaviour of AC and SCC should be considered as a biomarker supporting treatment
planning to select the patients, mainly with AC, that would most benefit from antiangiogenic therapies. The significance of results
was achieved by automatically detecting and excluding artefactual BF values.
1. Introduction
Tumorigenesis involves angiogenesis, a complex mechanism
consisting in the generation of a vascular network nour-
ishing the tumour that is highly disorganized [1]. Studying
abnormal vascular patterns, and their temporal changes, may
be essential for tissue characterization [2]. To this purpose,
the interest in CT perfusion (CTp) methodologies has been
recently confirmed [3], since CTp supplies both high spatial
and temporal resolution and allows computing perfusion
parameters from the analysis of the time concentration curves
(TCCs) [4], generated by the contrast agent reaching the
tumour. Among the most effective perfusion parameters
allowing angiogenesis evaluation [5], the blood flow (BF)
arises [6] mainly because of its high correlation with the
tissue biomarker microvessel density (MVD) [7]. BF can
be measured by considering only the first passage of the
contrast medium, this requiring a short-time examination
permitting tominimize the radiation dose given to the patient
[8, 9]. Clinical applications of BF information computed at
diagnosis include the lesion characterization [10], especially
relevant for inoperable patients, who need to schedule non-
surgical treatments [11]. Or else, higher baseline BF values in
patients with advanced lung carcinoma could suggest a better
response to therapy [12].
The differences in BF values between responders and
nonresponders have prompted a tumour hemodynamic
characterization, which also embodies cancer histological
subtypes. Characterizing the perfusion of non-small cell lung
cancer (NSCLC) has shown to provide useful information
concerning their status, in particular as regards their hypoxia
degree, deeply affecting tumour response to treatment [13].
In particular, it was shown that the adenocarcinoma (AC)
subtype has a significantly lower hypoxia degree than the
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squamous cell carcinoma (SCC) one [14]. Various perfusion
parameters have been reported to differ between lung cancer
subtypes [13, 15], showing discordant results [16–21]. How-
ever, when considering these discordant findings, we must
bear inmind that BF computation of lung tumours is exposed
to several sources of error [22], arising from respiratory
motion [23], CTp artefacts [24], and, not to forget, tumour
location [25], which can affect the reliability of BF values
[26], thus dimming the real nature of tumours and ham-
pering development and standardization of biomarkers. As
regards tumour location, its influence on BF values is rarely
considered in CTp studies. Nonetheless, it has been shown
that perfusion in central carcinomas is significantly lower
than in peripheral ones, due to the different recruitment of
vessels [27]. Nevertheless, also anatomical structures inside
lesion, such as vessels and bronchi, can be responsible for
jeopardizing perfusion analyses [26].
The aim of this study was to evaluate the characteristics
of lung tumour at diagnosis (i.e., at baseline condition),
newly investigating possible significant differences in perfu-
sion between AC and SCC, the two predominant NSCLC
phenotypes. Nevertheless, as previously shown, the literature
presents discordant results in AC and SCC perfusion char-
acterization, caused by too a high measurement variability,
stemming from clinical and physiological factors as well
as external causes (e.g., patient movements and artefacts).
To reduce such a variability, we automatically detected and
removed unreliable perfusion values. In addition, we exam-
ined lesions’ position, central or peripheral, and their prox-
imity to large vessels, studying whether and how this external
factor could artificially affect histotype perfusion. Finally, for
each histotype we also analyse the less representative lesions,
whose perfusion values are shifted to the group mean value
characterizing the other histotype.
2. Materials and Methods
Study Population. This study was approved by the Institu-
tional Review Board (IRB) that waived informed consent for
the retrospective data analysis of the patients. In addition,
a written consensus was obtained by all patients before
each study. Between September 2010 and April 2013, a total
of 32 consecutive patients (22 men, 10 women; age range
36-81 years) with primary NSCLC, subdivided in 24 AC
and 8 SCC, were identified and enrolled for data analysis.
Tumour stage was determined in all patients according to the
TNM classification of malignant tumours (seventh edition):
1 patient was diagnosed with stage IB, 3 patients with stage
IIIA, 5 patients with stage IIIB, and 23 patients with stage IV.
The patients included in this study were selected accord-
ing to the following criteria: over eighteen years old, with
histologically verified NSCLC, and no prior history of
chemotherapy, surgery, or thoracic radiation therapy. Patients
were excluded if the longest axial lesion diameter was less
than 10mm in at least one slice (n=2), if the examination
was severely affected by physics-based artefacts (n=4), in
case of a clinically significant cardiovascular disease and a
knownhistory of deep vein thrombus or pulmonary embolus.
The final population included 26 patients, 19 AC, and 7
SCC. Besides subtypes and staging, Table 1 includes lesion’s
location and position as the cancer features. For the sake of
completeness, we also report the widest axial tumour section.
CTp Protocol. At diagnosis, the patients underwent axial CT
perfusion (CTp) performed on a 256-slice CT system (Bril-
liance iCT, Philips Medical System, Best, The Netherlands),
feet first in the supine position. Initially, an unenhanced low-
dose full-body CT scan was performed to identify the target
lesion at baseline conditions.Then, a 50mL intravenous bolus
of contrast agent (Iomeron, Bracco, Milan, Italy) was injected
at 5mL/s for axial cine contrast-enhanced CT, followed by a
flushwith physiological saline solution (30mL), 5mL/s). Five
seconds later, each patient underwent a single acquisition
of duration 25 seconds under breath-hold condition. This
protocol yields 20 scans, each corresponding to different
sampling instants, with 55mm of z-coverage (11 slices × 5-
mm slice thickness, 0.4-sec rotation time, at 80 kV, 250mA,
100 mAs). Image data are reconstructed to 220 cine images
(512 × 512 pixel, 11 slices, 350mm × 350mm, 5-mm slice
spacing, 1.25-sec temporal resolution).
Perfusion Maps. A region of interest (ROI) in the descending
aorta was selected as the input function. A second ROI was
manually drawn in consensus [27] by two experienced radiol-
ogists (D.B. andG.G., 25-year experience each) on a reference
slice, where the tumour showed the widest area, similar to
whatwas done in [20, 27, 28].Then, for each lesion, the radiol-
ogists performed a 3D alignment according to the procedure
described in [29]. In order to obtain the TCCs relative to each
voxel, the values of the temporal sequence were fitted using
the sigmoid-shape model, arising from the Hill Equation
[30], and the random sampling method described in [31].
The curve fitting is achieved employing an in-house fitting
algorithm based on the nonlinear, least squares, Levenberg-
Marquardt minimization algorithm (lsqcurvefit, MATLAB©;
MathWorks, Natick, MA, USA). After TCCs computation,
BF values, expressed in mL/min/100 g, were computed for
AC and SCC subtypes using the maximum-slope method
[32, 33] by considering the first-pass phase only [34] and
representing each voxel with a one-compartment model,
including both the intravascular and the extravascular spaces
[35]. This allowed performing short-time examinations with
great benefits for patients, in terms of absorbed radiation dose
and examination quality, sincemotion artefacts were reduced
by the possibility for patients to hold their breath.
Nonetheless, in this paper, we propose two method-
ological approaches to improve the reliability of results,
that is, removing potential artefacts from perfusion maps
through an accurate data analysis and separately analysing the
“borderline cases”.
Data Analysis. Unreliable BF values were excluded from
the analysis and highlighted in the colour map with the
pink colour. In particular, BF values strictly lower than
1mL/min/100 g were automatically removed, being con-
sidered unlikely compliant with physiological values and
rather ascribable to numerical errors. Similarly, BF values
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Table 1: Summary of the histological diagnosis, tumour stage, position, location, and area of the widest tumour slice relative to each lesion.
Patient ID Diagnosis Stage Position Location Size [𝑐𝑚2]
ID1 AC IV Left Peripheral 2.4
ID2 AC IV Left Extended 15.9
ID3 AC IV Left Peripheral 4.6
ID4 AC IV Right Extended 7.0
ID5 AC IV Right Extended 16.1
ID6 AC IV Right Peripheral 15.0
ID7 AC IIIA Right Extended 5.9
ID8 AC IV Left Peripheral 1.5
ID9 AC IV Right Extended 29.0
ID10 AC IIIA Right Peripheral 2.5
ID11 AC IV Right Extended 20.3
ID12 AC IV Right Extended 3.9
ID13 AC IV Right Peripheral 0.6
ID14 AC IV Left Extended 2.5
ID15 AC IV Left Extended 10.8
ID16 AC IV Right Extended 1.9
ID17 AC IV Left Peripheral 1.5
ID18 AC IV Left Central 3.8
ID19 AC IIIB Right Central 10.7
ID20 SCC IB Left Peripheral 2.1
ID21 SCC IV Left Central 7.2
ID22 SCC IV Right Peripheral 5.2
ID23 SCC IIIB Right Central 10.3
ID24 SCC IIIB Right Extended 22.8
ID25 SCC IV Right Central 8.2
ID26 SCC IIIB Right Central 16.1
undergoing high TCC fitting errors due to the presence of
structures, such as blood vessels and bronchi, or dynamic
artefacts, were automatically detected as unreliable through
the method presented in [26]. Finally, mean BF values were
computed for each examination and considered to iden-
tify hemodynamic differences between the two histological
NSCLC subtypes, AC and SCC.
To better understand the implications of the denoising
methods we used, in Figure 1 we report two BF maps related
to ID15, obtained with the denoising method we used [26]
(a) and by manually removing (i.e., clipping) the highest BF
values (b), supposedly out of the physiological range, as it is
normally done. The removed values are shown in the pink
colour in both maps. As one can see, the denoising method
removes unreliable regions, including the outer ones, that
is, those suffering from partial volume effect, which pure
clipping normally keeps. Nevertheless, this method preserves
a range of BF values wider than clipping does.This behaviour
is underlined by the BF histogram of Figure 2(b), showing
that, by clipping, the highest BF values (in red) are removed
independently from their reliability, and the range of values
narrowed.On the other side, the BF histogramof Figure 2(a)
highlights the clear advantage of the denoising method,
which “saves” those high values which are generated with
no appreciable errors. Furthermore, one can see how this
method is able to even automatically remove unreliable low
values falling within the physiological BF range.This explains
why the range of BF values is wider, though the regions
removed have a wider extent. Although these two maps are
apparently very similar, the real benefit of the denoising
method definitely arises in the subsequent analysis. For
instance, as regards the perfusion analysis, themean BF value
of the clipped map (mean BF = 44.1mL/min/100 g) is smaller
than that of the corresponding denoised map (mean BF =
47.7mL/min/100 g) by almost 10%. This underestimation of
the mean BF value, due to the inclusion of unreliable BF
values and exclusion of high BF values regardless of their
reliability, could severely affect the statistical analysis of all
perfusion studies. Of course, in the presence of bronchi,
vessels, and, above all, artefacts this difference can be even
larger.
The “Borderline” Examinations. After performing the auto-
matic error analysis to detect and exclude unreliable values,
we looked for the causes that could affect the perfusion of the
“borderline” cases. Indeed, these are themost aspecific lesions
of the two classes, whose parameter values are nearest to
each other, which negatively affect the statistical significance
of the study. If from one side they could simply originate
from artefacts, from the other side, more interestingly, they
























Figure 1: Perfusionmaps of ID15 achieved through the use of the automatic denoisingmethod (a) and by hand clipping the highest BF values



































Figure 2: In blue, the histograms related to the original ID15 BF map and, in red, the BF values that were removed through the use of the
automatic denoising method (a) and by hand clipping the highest BF values (b).
can reflect the inherent variability of data and the intrinsic
tumour properties.
2.1. Assessment of Results. The main purpose of this work is
to determine whether AC and SCC are characterized by a
different baseline perfusion. In order to assess the statistical
significance of the differences in BF between AC and SCC
subtypes, the one-tail Welch’s t-test was used for mean, while
the one-tail Wilcoxon Rank Sum test (also known as Mann-
Whitney U-test) was used formedian. For both, the statistical
significance is achieved with p-value < 0.05. Statistical
analysis was performed using R software (version 3.0.1, The
R Foundation for Statistical Computing).
As regards the analysis of the borderline cases, we
examined several factors that may cause perfusion variability.
We considered where tumours arose, right or left lung, since
it is proved that they drain to different lymph node groups
according to their position [36]. In this context, we also
considered the tumour location, central or peripheral, since
central tumours can almost completely fed by the bronchial
circulation, while the peripheral tumours, mainly at their
early growth stage, can have a significant pulmonary con-
tribution [20]. Finally, we looked for the extrinsic effects on
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Table 2: BF stratified by NSCLC subtypes.
NSCLC Subtypes BF [mL/min/100 g]
Mean Median Minimum Maximum SD
AC 83.5 79.2 33.0 141.3 29.4
SCC 57.0 44.3 28.0 98.4 27.2




















Figure 3: Box plots showing the BF values of AC (left) and SCC
(right) lesions. The median is indicated as a red line in the boxes,
whereas the vertical size gives the interquartile range.
perfusion computation of beam hardening artefacts which,
for instance, occur in tumour localized near bony regions
of the chest and, also, where the contrast medium is highly
concentrated [24].
2.1.1. Tumour Location. For each examination, two radiol-
ogists examined the entire scan sequence so as to form in
their mind the morphological structure of the lesion, also
exploiting dynamic information. They divided tumours into
three groups according to their locations, also reporting if
they are in the left or right lung. A tumour was considered
peripherally located if it is 20mm of the costal pleura, within
the pulmonary parenchyma without direct connection to
mediastinal structures. A tumour is centrally located if it is
20mm of the mediastinal structures, in a close relationship
with the central airways. Otherwise, it is considered as an
extended tumour (that could be either large or small). The
two radiologists started by performing this analysis in double
blind and, then, they reviewed together all cases to reach an
agreement. This information is reported in Table 1.
3. Results
Table 2 resumes the main BF parameter values for AC
and SCC subtypes, while Figure 3 graphically shows the
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Figure 4: Mean BF values of AC (top) and SCC (bottom) examina-
tions (blue circles), along with the corresponding groupmean (solid
red line) and SD (solid green line) values.The green circles highlight
the examinations for each subtype that are closer to the mean value
of the other subtype.
highlights that the baseline BF mean value of AC exami-
nations is definitely greater than that of SCC ones (p-value
= 0.02), as well as the BF median value (p-value = 0.03).
Figure 4 shows the averaged BF values of each AC (top)
and SCC (bottom) examination. For reader’s convenience, the
samples have been joined and displayed with solid blue lines,
whereas the group mean and standard deviation (SD) values
are shown with solid red and green lines, respectively. As one
can see, as it often happens each subtype may have some
borderline examinations nearer to the group mean value of
the other subtype (the green disks in Figure 4), which are
responsible for reducing the statistical significance of the
between-group mean difference. In particular, ID5 (mean BF
= 50.5mL/min/100 g), ID10 (mean BF = 32.9mL/min/100 g),
and ID15 (mean BF = 47.7mL/min/100 g) are three AC
examinations whose BF values are closer to the SCC group
mean value, while ID23 (mean BF = 89.7mL/min/100 g) and
ID26 (mean BF = 98.5mL/min/100 g) are two SCCs with
mean values closer to AC groupmean. In the next section, we
consider other studies aiming at assessing perfusion values
of AC and SCC, besides these borderline cases, which are
analysed to assess whether their mean value really reflects
phenotypical features.




































Figure 6: Reference slice and perfusion map related to ID5 (a, b) and ID15 (c, d). In pink, the unreliable values.
4. Discussion
In the literature, studies concerning the perfusion charac-
terization of AC and SCC report contrasting results. The
authors in [16] indicate that AC is characterized by a more
abundant blood supply than SCC, as the higher peak of their
TCCs suggested. Moreover, also blood volume and flow-
extraction product are significantly higher in AC than in SCC
[14]. The authors in [17] also found that AC has apparently
a higher perfusion than SCC, but these results were not
statistically significant, although MVD is significantly more
intense in AC than in SCC. Other studies [18–20] highlighted
no differences in perfusion parameters among these two
histological subtypes, also finding that they are characterized
by a similar MVD [21].
Among the possible causes for these discordant results,
we propose to consider also those borderline cases whose
perfusion values might be ascribed to motivation other than
their phenotypical features.Thefirst comment concerns ID10,
the AC lesion characterized by the lowest perfusion and
shown in Figure 5. This lesion is a very small peripheral
carcinoma, one of the smallest examined, located in the
subpleural parenchyma, probably characterized by a predom-
inant pulmonary circulation, which could not have activated
the angiogenesis process yet [37]. As regards the other two
AC lesions with a low perfusion, ID5 in Figure 6(a) and
ID15 in Figure 6(b), these share similar properties that could
explain their low perfusion. In fact, both of them are large
and extended lesions, presenting wide low-perfusion regions,
maybe suggesting hypoxia, which lower the mean BF values.
Altogether, these three cases seem not showing any external
characteristic artificially altering their BF. For instance, ID19
(mean BF = 141.4mL/min/100 g) is a central carcinoma, as
large as ID15, with a high perfusion value (the highest one).
As amatter of fact, lesions of such a dimension are often char-
acterized by a hypoxic core, due to the presence of weak and
disorganized capillaries characterizing tumour angiogenesis.
These vessels, being more permeable than normal, increase
the liquid of the extravascular space, causing the adjacent
cells moving away from the vessels and, consequently, the low
oxygenation of the surrounding tissue.However, the presence
of segmental vessels inside ID19 still nourished the core of the
lesion.
As far as SCC are concerned, the two examinations ID23
and ID26 (Figure 7), showing a higher perfusion compared
to the others SCC, share a common feature. Indeed, they
are both central SCC lesions positioned at the right lung,
directly connected to the vena cava and the pulmonary
artery, respectively. This particular location, in proximity of
these large blood vessels, may yield several artefacts during
image acquisition, as shown in the original slices of Figure 7,
which are responsible for an artificial increasing of BF values.
A detail of six artefactual slices of ID23, referred to the
same couch position, is shown in Figure 8. Nonetheless, one
other central lesion, ID25 (mean BF = 59.3mL/min/100 g) in
Figure 9(a), suffers from moderate artefacts, while the last
one, ID21 (mean BF = 42.0mL/min/100 g) in Figure 9(b), is
not artefactual. It is worth mentioning that if the artefacts

























Figure 7: Reference slice and perfusion map related to ID23 (a, b) and ID26 (c, d). In pink, the unreliable values.


















Figure 9: Reference slice and perfusion map related to ID25 (a, b) and ID21 (c, d). In pink, the unreliable values.
in ID23, ID25, and ID26 were removed manually, BF values
for SCCs would rise to mean BF = 63.5mL/min/100 g and
SD BF = 36.9mL/min/100 g, this yielding the difference
between the overall means of the histotypes not to be
statistically significant (p-value = 0.08). As a marginal note,
it is interesting to see how the SCC lesion characterized by
the lowest mean BF value in our court, ID20 (mean BF =
28.0mL/min/100 g), shown in Figure 10, is staged IB.
At the end, we analysed themean BF values of each lesion
in relation to position and location.We report that each of the
four peripheral ACs in the left lung has a mean value greater
than the group mean, and the three right peripheral lesions
have a lower mean BF, probably because of two bronchial
arteries usually running to the left lung, while one only to the
right lung. Similarly, all the extended AC lesions, neglecting
their position, have a mean value lower than the groupmean,
except for ID2 and ID11 (Figures 11(a) and 11(b), respectively),
that represent large lesions undergoing light beam hardening
artefacts, from left and right atrium, respectively.
The present study newly investigated the perfusion base-
line characteristics of AC and SCC, the two major NSCLC
subtypes, after that the literature has reported discordant
outcomes. We addressed the BF mean value, commonly used
as significant statistical parameter in several studies [7, 38].
Our results show that, before treatments, the AC histological
type has a BF mean value significantly greater than SCC
subtype, which generally shows a lower perfusion associated
with an increased presence of necrotic areas. These results
arise from the reliability analysis of the BF maps and are
enforced by the analysis of borderline cases.
The reliability assessment, carried out through an auto-
matic and objective error detection method [26], allowed
removing the anatomical structures (mainly blood vessels
and bronchi) and regions undergoing artefacts that could
compromise the correct interpretation of perfusion maps,
thus considerably improving their reliability. In particular,
automatically removing and excluding all the artefactual
regions from the subsequent analysis is probably the main
reason why this study found a clear statistical significance of
the different BF properties of AC and SCC histotypes.
Besides improving perfusion reliability, we analytically
examined the borderline cases, that is, those most aspecific
examinations of the two histotypes, whose perfusion values
are so near to the mean value of the other histotype as to
partly lose their representativeness. In particular, we looked
for some external causes, besides phenotypical properties,













Figure 10: Reference slice (a) and perfusion map (b) related to ID20. In pink, the unreliable values.
(a) (b)
Figure 11: AC examinations ID2 (a) and ID11 (b) undergoing beam hardening artefacts.
which could motivate the mean BF value of each borderline
case. As far as the three ACs are concerned, we could not
find any external cause that could explain their lower BF
values. Rather, the wide range covered by the AC histo-
type could be suggestive of the existence of subpopulations
with different perfusion behaviours. Although there is no
statistical evidence regarding probable effects of tumour’s
position and location on the BF mean values, we found
some interesting tendencies regarding subgroups of the AC
histotypes that could support this hypothesis and are worth
investigating separately in a dedicated study. On the contrary,
the predominantly central position of SCCs makes them
prone to beam hardening artefacts, due to high contrast
medium concentration in large neighbouring vessels, such as
vena cava and the pulmonary artery. Indeed, it is known that
artefacts may yield false results in tumours localized near to
large central vessels [27]. In particular, we proved thatwithout
automatically removing those artefactual regions from per-
fusion computation in two borderline SCCs, their BF mean
values would expectedly be higher so as that the difference
between AC and SCC means would not be significant any
more. This could explain the discordant results emerging
in the literature regarding the perfusion characterization of
these lung cancer subtypes, since the “noise” emerging from
the colour maps was almost disregarded. As an example, the
study carried out in [15] reports group mean and SD BF
values for AC (74.7 ± 28.2mL/min/100 g) and SCC (68.7 ±
32.1mL/min/100 g) that are so near to each other as to
conclude that their difference is not statistically significant.
However, a deep analysis of SCCs could highlight that they
underwent artefacts and using our same method to remove
them could have led to the opposite conclusion.
As an added value of this research, we want to stress how
these results have been achieved using a short-time, dose-
saving, protocol that could foster other studies aiming at
investigating the peculiarities of AC subgroups, as far as BF
is concerned. Nonetheless, increasing the examination time
would jeopardize the possibility for patients to hold their
breath, and motion artefacts introduced after a 25-sec period
would worsen the quality of the image sequence [27].
This study has also some limitations. The first is the
relatively small cohort of patients. However, other works in
the literature reported a similar number of examinations,
such as that in [38] (22 AC, 8 SCC), or smaller, like in [18]
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(14 AC, 9 SCC), [20] (18 AC, 5 SCC), and [14] (6 AC, 8
SCC). Nonetheless, removing the unreliable perfusion values
improved the statistical significance of the examinations at
our disposal. The second limitation stems from the first one,
as the number of examinations prevented us from exploring
BF properties of possible AC subgroups. Finally, we have
studied the BF only. However, considering other parameters
was beyond the purpose of this research.
5. Conclusions
The main purpose of this work was to investigate the BF
properties of AC and SCC at diagnosis, before treatment, and
clear perfusion differences emerged from these NSCLC can-
cer subtypes that should be considered during their treatment
planning. Nonetheless, we introduced two methodological
contributions that allowed this study, with a non-large size
cohort and a short-time protocol, to achieve a clear outcome.
These contributions, which could benefit other cancer perfu-
sion studies, consist in the use of a method to improve the
reliability of single examinations and the accurate analysis of
those borderline lesions less characterizing for the histotype
they belong to. In particular, we believe it is important to
explicitly investigate the causes that may be responsible for
those values because, besides permitting to detect values that
are artificially high (or low), the borderline lesions could
contain even more valuable information than the other ones.
Among the practical advantages, the capability of achiev-
ing more accurate results could prevent the need of using a
higher tube voltage, for instance, when investigating central
carcinomas, which reduces the sensitivity to the contrast
medium and increases the exposure of the patient [27].
We encourage the authors of all the previous studies on
AC and SCC to review their analysis in the light of the
methodological approaches presented in this research. In
this age of personalised medicine, a non-invasive profiling of
the tumour in terms of perfusion characteristics, apparently
an independent surrogate biomarker, could have important
implications in treatment strategy, particularly in the identi-
fication of the patients, mainly with AC, that will most benefit
from antiangiogenic therapies.
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